These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 10444162)
1. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. Sweetenham J; Hieke K; Kerrigan M; Howard P; Smartt PF; McIntyre AM; Townshend S Br J Haematol; 1999 Jul; 106(1):47-54. PubMed ID: 10444162 [TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Ferrara F; Ravasio R Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361 [TBL] [Abstract][Full Text] [Related]
4. Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study. Hutchinson J; Lloyd A; Gray A; Gale R; Hancock B Acta Haematol; 2006; 115(1-2):28-34. PubMed ID: 16424646 [TBL] [Abstract][Full Text] [Related]
5. Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment. Herold M; Hieke K Value Health; 2003; 6(2):167-74. PubMed ID: 12641867 [TBL] [Abstract][Full Text] [Related]
6. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Hornberger JC; Best JH Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658 [TBL] [Abstract][Full Text] [Related]
8. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F Value Health; 2005; 8(4):462-70. PubMed ID: 16091023 [TBL] [Abstract][Full Text] [Related]
10. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Knight C; Hind D; Brewer N; Abbott V Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313 [TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy]. Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040 [TBL] [Abstract][Full Text] [Related]
13. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y; Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866 [TBL] [Abstract][Full Text] [Related]
15. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035 [TBL] [Abstract][Full Text] [Related]
16. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. Persky DO; Unger JM; Spier CM; Stea B; LeBlanc M; McCarty MJ; Rimsza LM; Fisher RI; Miller TP; J Clin Oncol; 2008 May; 26(14):2258-63. PubMed ID: 18413640 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Tobinai K; Ishizawa K; Ogura M; Itoh K; Morishima Y; Ando K; Taniwaki M; Watanabe T; Yamamoto J; Uchida T; Nakata M; Terauchi T; Nawano S; Matsusako M; Hayashi M; Hotta T Cancer Sci; 2009 Oct; 100(10):1951-6. PubMed ID: 19594547 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma]. Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800 [TBL] [Abstract][Full Text] [Related]
20. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387 [No Abstract] [Full Text] [Related] [Next] [New Search]